Related Experiment Video
Updated: May 12, 2025
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Protective Effects of Probiotics Against Systemic Inflammation in Mice Model with Chronic Obstructive Pulmonary
Andika Pradana1,2, Dina Keumala Sari3, Muhammad Rusda1,4
1Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Background:
Systemic inflammation is one of hallmarks in chronic obstructive pulmonary disease (COPD), contributing to high morbidity and mortality due to elevated levels of interleukin-6 (IL-6) and reduced level of interleukin-10 (IL-10). Probiotics have the potential to reduce systemic inflammation through the gut-lung axis. This study aims to assess the effect of probiotics compared with an inhaled bronchodilator on serum IL-6 and IL-10 levels in mice model of COPD.
Methods:
This was an in vivo experimental study with a post-test only control group design. Thirty C57BL/6 mice were randomized into five groups; NC (healthy mice), PC (COPD induced mice); T1 (COPD mice treated with a bronchodilator), T2 (COPD mice treated with probiotics) and T3 (COPD mice treated with both a bronchodilator and probiotics). COPD was induced for 12 weeks, followed by a 6-week treatment period. After completing the treatment, serum IL-6 and IL-10 levels were measured using the enzyme-linked immunosorbent assay (ELISA).
Results:
The IL-6 levels in T2 group were reduced to levels comparable to the negative control group (13.5 vs 12.0 pg/ml respectively, p=0.84). The IL-10 levels were higher in T2 group compared to T1 group, however; this difference was not statistically significant (181.4 vs 155.0 respectively, p>0.05).
Conclusions:
In mice model of COPD, probiotics have been shown to lower IL-6 levels and, to a lesser extent, increased IL-10. As a result, probiotics may have a protective effect against systemic inflammation.
